BioPlus Acquisition Corp

BioPlus Acquisition Corp. is an early stage blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying an opportunity in the life sciences industry. The company was founded on February 11, 2021 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the “Business Combination Agreement”), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering (“Public Shares”).

BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

- Transaction values Avertix at an enterprise value of $195 million - Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events, including silent heart attacks

Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading tomorrow, Friday, December 3, 2021, under the ticker symbol “BIOSU”. Each unit consists one of the Company's Class A ordinary shares and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one of the Company's Class A ordinary shares at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “BIOS” and “BIOSW,” respectively.

BioPlus Acquisition Corp. Announces Pricing of Upsized $200,000,000 Initial Public Offering

BANNOCKBURN, Ill., Feb.  03, 2020  (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today that it has completed the reverse 1-for-4 stock split of its shares of common stock, as previously disclosed in the Company’s filings with the Securities and Exchange Commission.  As of market open on February 3, 2020, the Company’s common stock, which was previously listed on the Nasdaq Capital Market under the symbol “BIOS”, will begin trading on a split-adjusted basis on the Nasdaq Global Select Market under the ticker symbol “OPCH” and will be assigned a new CUSIP number (68404L 201).

Option Care Health Completes Reverse Stock Split and Ticker Symbol Change

Option Care (BIOS) reported earnings 30 days ago. What's next for the stock?

Option Care (BIOS) Down 12% Since Last Earnings Report: Can It Rebound?

Option Care Health (BIOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Option Care Health (BIOS) Surges: Stock Moves 7.3% Higher

Option Care Health (BIOS) can currently access all hemophilia factor treatments.

Option Care is the Preferred Provider of Haemophilia Treatment

National leader in treating bleeding disorders offers personalized, high-quality patient care National leader in treating bleeding disorders offers personalized, high-quality patient care

Option Care Health Selected by Highmark  as Preferred Provider of Hemophilia Treatment

Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.

Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top

Option Care Health, Inc (BIOS) CEO John Rademacher on Q3 2019 Results - Earnings Call Transcript

Option Care (BIOS) delivered earnings and revenue surprises of 0.00% and 17.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Option Care (BIOS) Reports Q3 Loss, Tops Revenue Estimates

Option Care (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Option Care (BIOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Option Care Health is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Option Care Health

Alexco Resource

Photronics

Tech Data

Top Ranked Momentum Stocks to Buy for September 12th

As of late, it has definitely been a great time to be an investor in BioScrip, Inc. (BIOS).

BioScrip, Inc. (BIOS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in BioScrip.

BioScrip, Inc.'s Shares March Higher, Can It Continue?

BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock?

BioScrip (BIOS) Up 5.2% Since Last Earnings Report: Can It Continue?

BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.

BioScrip's Option Care Merger on Track, Q1 Loss Narrows

BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates

BioScrip, Inc. (BIOS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: BioScrip

Why Is BioScrip (BIOS) Down 50.4% Since Last Earnings Report?

Shares of BioScrip Inc. tumbled 9.0% toward a 9-month low in midday trade Monday.

BioScrip's stock extends plunge after merger terms disappoint, but analyst recommends remaining bullish

Adobe

Ascena Retail Group

Earnings and other bad news kept these stocks out of today's rally.

Why Adobe, BioScrip, and Ascena Retail Group Slumped Today

BioScrip's fourth-quarter results and merger with Option Care Enterprises aren't sitting well with shareholders.

News for BioPlus Acquisition Corp Stock (BIOS)